Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome
Tóm tắt
Từ khóa
Tài liệu tham khảo
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Breast Cancer Version 3.2013. May 3, 2013.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Kidney Cancer Version 1.2013. Dec 5, 2013.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Colon Cancer Version 3.2013. Nov 26, 2012.
Mottet N, Bastian PJ, Bellmunt J, et al. Arnhem (The Netherlands): European Association of Urology (EAU). Guidelines on prostate cancer. 2014; 172.
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Prostate Cancer Version 2.2014. Jan 4, 2014.
Bonkhoff, 2007, From pathogenesis to prevention of castration resistant prostate cancer, Prostate, 70, 100, 10.1002/pros.21042
Kruck, 2012, Circulating and disseminated tumor cells in the management of advanced prostate cancer, Adv Urol, 2012, 135281, 10.1155/2012/135281
Haffner, 2013, Tracking the clonal origin of lethal prostate cancer, J Clin Invest, 123, 4918, 10.1172/JCI70354
Tzelepi, 2011, Persistently, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment, J Clin Oncol, 29, 2574, 10.1200/JCO.2010.33.2999
Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487
Elias, 2005, Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter but their total number has a prognostic effect, Ann Surg Oncol, 12, 900, 10.1245/ASO.2005.01.010
Verwaal, 2008, 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer, Ann Surg Oncol, 15, 2426, 10.1245/s10434-008-9966-2
Elias, 2010, Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study, J Clin Oncol, 28, 63, 10.1200/JCO.2009.23.9285
Babiera, 2006, Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor, Ann Surg Oncol, 13, 776, 10.1245/ASO.2006.03.033
Fields, 2007, Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis, Ann Surg Oncol, 14, 3345, 10.1245/s10434-007-9527-0
Blanchard, 2008, Association of surgery with improved survival in stage IV breast cancer patients, Ann Surg, 247, 732, 10.1097/SLA.0b013e3181656d32
Le Scodan, 2009, Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy, J Clin Oncol, 27, 1375, 10.1200/JCO.2008.19.5396
Gjertson, 2007, Local control and long-term disease-free survival for stage d1 (t2-t4n1-n2m0) prostate cancer after radical prostatectomy in the PSA era, Urology, 70, 723, 10.1016/j.urology.2007.05.014
Verhagen, 2010, Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review, Eur Urol, 58, 261, 10.1016/j.eururo.2010.05.027
Kyrdalen, 2013, A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer, BJU Int, 111, 221, 10.1111/j.1464-410X.2012.11198.x
Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012
Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the Munich cancer registry, Eur Urol, 66, 602, 10.1016/j.eururo.2014.04.009
Engel, 2010, Survival benefit of radical prostatectomy in lymph-node positive patients with prostate cancer, Eur Urol, 57, 754, 10.1016/j.eururo.2009.12.034
Gakis, 2013, The role of radical prostatectomy and lymph node dissection in lymph node positive prostate cancer: a systematic review of the literature, Eur Urol, 66, 191, 10.1016/j.eururo.2013.05.033
Mitin, 2013, Management of lymph node-positive prostate cancer: the role of surgery and radiation therapy, Oncology (Williston Park), 27, 647
A prospective, multi-institutional, randomized, phase ii trial of best systemic therapy or best systemic therapy (BST) plus definitive treatment (radiation or surgery) of the primary tumor in metastatic (M1) prostate cancer (PC). (NCT01751438).
A prospective randomized phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patients with metastatic hormone-naïve prostate cancer (PEACE-1) (NCT01957436).
Fizazi, 2014, Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe., Eur Urol
A prospective, randomised study into the effect on survival of hormonal treatment versus hormonal treatment plus local external radiotherapy in patients with primary metastatic (bone) prostate cancer (the HORRAD study) (ISRCTN06890529).
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: evaluation of drug efficacy: a Multi-Stage Multi-Arm Randomised Controlled Trial (NCT00268476).
James, 2014, Impact of node status and radiotherapy on failure-free survival in patients with newly diagnosed non-metastatic prostate cancer: data from>690 patients in the control arm of the STAMPEDE trial, Ann Oncol, 25, 10.1093/annonc/mdu336.2
Sweeney, 2014, Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial., J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.lba2